Following IPO, Dova puts lead drug in FDA ’s hands

Following its initial public offering – which yielded net proceeds of about $80 million – Durham-based Dova Pharmaceuticals has submitted a new drug application to the U.S. Drug Administration for its lead drug.
Source: bizjournals.com Health Care News Headlines - Category: Health Management Authors: Source Type: news